Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.

Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. 

The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. 

With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVIDIA and Gaingels.   


Biotechnology

Life Sciences

Pharmaceutical

Superluminal Medicines Inc.

Superluminal Medicines Inc.'s headquarters in Boston, United States

Description

People (6)

Ajay Yekkirala

Min-Sun Park

Yamina Berchiche

Dylan Morris

Ryan Bloom

Mark Fitzgerald

Jobs